Literature DB >> 34232575

Pharmacogenomics in Cardiovascular Diseases.

Caitrin W McDonough1.   

Abstract

Cardiovascular pharmacogenomics is the study and identification of genomic markers that are associated with variability in cardiovascular drug response, cardiovascular drug-related outcomes, or cardiovascular drug-related adverse events. This overview presents an introduction and historical background to cardiovascular pharmacogenomics, and a protocol for designing a cardiovascular pharmacogenomics study. Important considerations are also included for constructing a cardiovascular pharmacogenomics phenotype, designing the replication or validation strategy, common statistical approaches, and how to put the results in context with the cardiovascular drug or cardiovascular disease under investigation.
© 2021 Wiley Periodicals LLC. Basic Protocol: Designing a cardiovascular pharmacogenomics study. © 2021 Wiley Periodicals LLC.

Entities:  

Keywords:  antihypertensive therapy; antiplatelet therapy; cardiovascular; complex diseases; pharmacogenomics

Mesh:

Substances:

Year:  2021        PMID: 34232575      PMCID: PMC8344365          DOI: 10.1002/cpz1.189

Source DB:  PubMed          Journal:  Curr Protoc        ISSN: 2691-1299


  66 in total

Review 1.  Institutional profile: University of Florida Health Personalized Medicine Program.

Authors:  Larisa H Cavallari; Kristin W Weitzel; Amanda R Elsey; Xinyue Liu; Scott A Mosley; Donald M Smith; Benjamin J Staley; Almut G Winterstein; Carol A Mathews; Francesco Franchi; Fabiana Rollini; Dominick J Angiolillo; Petr Starostik; Michael J Clare-Salzler; David R Nelson; Julie A Johnson
Journal:  Pharmacogenomics       Date:  2017-03-27       Impact factor: 2.533

2.  A randomized and clinical effectiveness trial comparing two pharmacogenetic algorithms and standard care for individualizing warfarin dosing (CoumaGen-II).

Authors:  Jeffrey L Anderson; Benjamin D Horne; Scott M Stevens; Scott C Woller; Kent M Samuelson; Justin W Mansfield; Michelle Robinson; Stephanie Barton; Kim Brunisholz; Chrissa P Mower; John A Huntinghouse; Jeffrey S Rollo; Dustin Siler; Tami L Bair; Stacey Knight; Joseph B Muhlestein; John F Carlquist
Journal:  Circulation       Date:  2012-03-19       Impact factor: 29.690

3.  Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label, multicentre trial.

Authors:  Dirk Sibbing; Dániel Aradi; Claudius Jacobshagen; Lisa Gross; Dietmar Trenk; Tobias Geisler; Martin Orban; Martin Hadamitzky; Béla Merkely; Róbert Gábor Kiss; András Komócsi; Csaba A Dézsi; Lesca Holdt; Stephan B Felix; Radoslaw Parma; Mariusz Klopotowski; Robert H G Schwinger; Johannes Rieber; Kurt Huber; Franz-Josef Neumann; Lukasz Koltowski; Julinda Mehilli; Zenon Huczek; Steffen Massberg
Journal:  Lancet       Date:  2017-08-28       Impact factor: 79.321

4.  A Genotype-Guided Strategy for Oral P2Y12 Inhibitors in Primary PCI.

Authors:  Daniel M F Claassens; Gerrit J A Vos; Thomas O Bergmeijer; Renicus S Hermanides; Arnoud W J van 't Hof; Pim van der Harst; Emanuele Barbato; Carmine Morisco; Richard M Tjon Joe Gin; Folkert W Asselbergs; Arend Mosterd; Jean-Paul R Herrman; Willem J M Dewilde; Paul W A Janssen; Johannes C Kelder; Maarten J Postma; Anthonius de Boer; Cornelis Boersma; Vera H M Deneer; Jurriën M Ten Berg
Journal:  N Engl J Med       Date:  2019-09-03       Impact factor: 91.245

5.  Impaired (S)-warfarin metabolism catalysed by the R144C allelic variant of CYP2C9.

Authors:  A E Rettie; L C Wienkers; F J Gonzalez; W F Trager; K R Korzekwa
Journal:  Pharmacogenetics       Date:  1994-02

6.  Interaction between polymorphisms in the renin-angiotensin-system and angiotensin-converting enzyme inhibitor or beta-blocker use and the risk of myocardial infarction and stroke.

Authors:  H Schelleman; O H Klungel; J C M Witteman; M M B Breteler; A Hofman; C M van Duijn; A de Boer; B H Ch Stricker
Journal:  Pharmacogenomics J       Date:  2008-03-18       Impact factor: 3.550

7.  Antihypertensive pharmacogenetic effect of fibrinogen-beta variant -455G>A on cardiovascular disease, end-stage renal disease, and mortality: the GenHAT study.

Authors:  Amy I Lynch; Eric Boerwinkle; Barry R Davis; Charles E Ford; John H Eckfeldt; Catherine Leiendecker-Foster; Donna K Arnett
Journal:  Pharmacogenet Genomics       Date:  2009-06       Impact factor: 2.089

8.  Association of variants in NEDD4L with blood pressure response and adverse cardiovascular outcomes in hypertensive patients treated with thiazide diuretics.

Authors:  Caitrin W McDonough; Sarah E Burbage; Julio D Duarte; Yan Gong; Taimour Y Langaee; Stephen T Turner; John G Gums; Arlene B Chapman; Kent R Bailey; Amber L Beitelshees; Eric Boerwinkle; Carl J Pepine; Rhonda M Cooper-DeHoff; Julie A Johnson
Journal:  J Hypertens       Date:  2013-04       Impact factor: 4.844

9.  Multisite Investigation of Outcomes With Implementation of CYP2C19 Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention.

Authors:  Larisa H Cavallari; Craig R Lee; Amber L Beitelshees; Rhonda M Cooper-DeHoff; Julio D Duarte; Deepak Voora; Stephen E Kimmel; Caitrin W McDonough; Yan Gong; Chintan V Dave; Victoria M Pratt; Tameka D Alestock; R David Anderson; Jorge Alsip; Amer K Ardati; Brigitta C Brott; Lawrence Brown; Supatat Chumnumwat; Michael J Clare-Salzler; James C Coons; Joshua C Denny; Chrisly Dillon; Amanda R Elsey; Issam S Hamadeh; Shuko Harada; William B Hillegass; Lindsay Hines; Richard B Horenstein; Lucius A Howell; Linda J B Jeng; Mark D Kelemen; Yee Ming Lee; Oyunbileg Magvanjav; May Montasser; David R Nelson; Edith A Nutescu; Devon C Nwaba; Ruth E Pakyz; Kathleen Palmer; Josh F Peterson; Toni I Pollin; Alison H Quinn; Shawn W Robinson; Jamie Schub; Todd C Skaar; D Max Smith; Vindhya B Sriramoju; Petr Starostik; Tomasz P Stys; James M Stevenson; Nicholas Varunok; Mark R Vesely; Dyson T Wake; Karen E Weck; Kristin W Weitzel; Russell A Wilke; James Willig; Richard Y Zhao; Rolf P Kreutz; George A Stouffer; Philip E Empey; Nita A Limdi; Alan R Shuldiner; Almut G Winterstein; Julie A Johnson
Journal:  JACC Cardiovasc Interv       Date:  2017-11-01       Impact factor: 11.195

10.  Multisite Investigation of Strategies for the Implementation of CYP2C19 Genotype-Guided Antiplatelet Therapy.

Authors:  Philip E Empey; James M Stevenson; Sony Tuteja; Kristin W Weitzel; Dominick J Angiolillo; Amber L Beitelshees; James C Coons; Julio D Duarte; Francesco Franchi; Linda J B Jeng; Julie A Johnson; Rolf P Kreutz; Nita A Limdi; Kristin A Maloney; Aniwaa Owusu Obeng; Josh F Peterson; Natasha Petry; Victoria M Pratt; Fabiana Rollini; Stuart A Scott; Todd C Skaar; Mark R Vesely; George A Stouffer; Russell A Wilke; Larisa H Cavallari; Craig R Lee
Journal:  Clin Pharmacol Ther       Date:  2018-01-30       Impact factor: 6.875

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.